<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>领星GenomiCare | wechat-feeds</title><link>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</link><description>领星是由中美生物医学数据科学家携手高年资肿瘤专家共同开创的临床科技和数据平台，提供肿瘤精准医疗和数据智能服务。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 03 Mar 2021 14:09:15 +0800</pubDate><image><url>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</url><title>领星GenomiCare | wechat-feeds</title><link>http://MzI1NTQ2ODc0Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>临床试验 | 胃癌（五）</title><link>https://mp.weixin.qq.com/s/ANzus-wyE3hL3QWUcZ2xSw</link><description></description><content:encoded><![CDATA[临床试验 | 胃癌（五）]]></content:encoded><pubDate>Wed, 03 Mar 2021 11:16:11 +0800</pubDate></item><item><title>文献精读丨单细胞多组学揭示结直肠癌基因突变图谱</title><link>https://mp.weixin.qq.com/s/cZCtvlTs8PAXu-P6hmV4Xg</link><description></description><content:encoded><![CDATA[文献精读丨单细胞多组学揭示结直肠癌基因突变图谱]]></content:encoded><pubDate>Tue, 02 Mar 2021 11:08:45 +0800</pubDate></item><item><title>速递丨默沙东从康方生物引进的CTLA-4单抗联合疗法在华获批临床</title><link>https://mp.weixin.qq.com/s/dkI019ymB34-JM5Y6CuUaA</link><description></description><content:encoded><![CDATA[速递丨默沙东从康方生物引进的CTLA-4单抗联合疗法在华获批临床]]></content:encoded><pubDate>Tue, 02 Mar 2021 11:08:45 +0800</pubDate></item><item><title>星月当空照，阖家共元宵丨领星祝您节日快乐！</title><link>https://mp.weixin.qq.com/s/KoJRvoneV0D-mfJsuZYPGA</link><description></description><content:encoded><![CDATA[星月当空照，阖家共元宵丨领星祝您节日快乐！]]></content:encoded><pubDate>Fri, 26 Feb 2021 09:23:47 +0800</pubDate></item><item><title>关于肝癌的7个疑问，你一定也有！</title><link>https://mp.weixin.qq.com/s/ixahrwIai06h7B9GFuDIrQ</link><description></description><content:encoded><![CDATA[关于肝癌的7个疑问，你一定也有！]]></content:encoded><pubDate>Thu, 25 Feb 2021 15:55:02 +0800</pubDate></item><item><title>速递丨阿斯利康1类新药治疗乳腺癌在华获批临床</title><link>https://mp.weixin.qq.com/s/C9Zo_pv1cnYOGJdMWUtMwg</link><description></description><content:encoded><![CDATA[速递丨阿斯利康1类新药治疗乳腺癌在华获批临床]]></content:encoded><pubDate>Thu, 25 Feb 2021 15:55:02 +0800</pubDate></item><item><title>临床试验丨 晚期或转移性尿路上皮癌（五）</title><link>https://mp.weixin.qq.com/s/9_Q68lYetRJDrj4A3kCj5w</link><description></description><content:encoded><![CDATA[临床试验丨 晚期或转移性尿路上皮癌（五）]]></content:encoded><pubDate>Wed, 24 Feb 2021 10:48:31 +0800</pubDate></item><item><title>脑脊液ctDNA检测-攻克小儿神经髓母细胞瘤 精准诊疗难题</title><link>https://mp.weixin.qq.com/s/Tmqk-TnYIOnqvVgNrN6wKw</link><description></description><content:encoded><![CDATA[脑脊液ctDNA检测-攻克小儿神经髓母细胞瘤 精准诊疗难题]]></content:encoded><pubDate>Tue, 23 Feb 2021 10:38:50 +0800</pubDate></item><item><title>速递丨太阳药业在华提交抗癌新药上市申请！TCR疗法获FDA突破性疗法认定！</title><link>https://mp.weixin.qq.com/s/KRNA7mRYBfuzhjZEZDHQGg</link><description></description><content:encoded><![CDATA[速递丨太阳药业在华提交抗癌新药上市申请！TCR疗法获FDA突破性疗法认定！]]></content:encoded><pubDate>Tue, 23 Feb 2021 10:38:50 +0800</pubDate></item><item><title>医保抗肿瘤药目录调整，不同癌种受什么影响？</title><link>https://mp.weixin.qq.com/s/AGMfYeZNmxekaUWQCyhMqA</link><description></description><content:encoded><![CDATA[医保抗肿瘤药目录调整，不同癌种受什么影响？]]></content:encoded><pubDate>Sat, 20 Feb 2021 10:22:21 +0800</pubDate></item><item><title>速递丨君实生物PD-1二线治疗鼻咽癌在华获批；纳武利尤单抗CheckMate -274研究达到主要终点！</title><link>https://mp.weixin.qq.com/s/nC8vdhRiHkezBBBCh3-ZOQ</link><description></description><content:encoded><![CDATA[速递丨君实生物PD-1二线治疗鼻咽癌在华获批；纳武利尤单抗CheckMate -274研究达到主要终点！]]></content:encoded><pubDate>Sat, 20 Feb 2021 10:22:21 +0800</pubDate></item><item><title>同一个位置同一种治疗-RAS、BRAF突变与否可能具有完全相反的治疗结果</title><link>https://mp.weixin.qq.com/s/UVOET-ELmezem9ZO8NphZQ</link><description></description><content:encoded><![CDATA[同一个位置同一种治疗-RAS、BRAF突变与否可能具有完全相反的治疗结果]]></content:encoded><pubDate>Fri, 19 Feb 2021 09:24:01 +0800</pubDate></item><item><title>领星祝您牛年畅快笑，平安福星照！</title><link>https://mp.weixin.qq.com/s/yzLTaax1AIrp9KDZl_bpbw</link><description></description><content:encoded><![CDATA[领星祝您牛年畅快笑，平安福星照！]]></content:encoded><pubDate>Wed, 10 Feb 2021 23:07:02 +0800</pubDate></item><item><title>免疫or化疗，MSI-H晚期肠癌患者 一线治疗该如何选择？</title><link>https://mp.weixin.qq.com/s/vWYCWaqixxzQ8-muuCNHww</link><description></description><content:encoded><![CDATA[免疫or化疗，MSI-H晚期肠癌患者 一线治疗该如何选择？]]></content:encoded><pubDate>Mon, 08 Feb 2021 13:24:33 +0800</pubDate></item></channel></rss>